List of Excipients in Branded Drug CEFPODOXIME PROXETIL

Generic Drugs Containing CEFPODOXIME PROXETIL

Company	Ingredient	NDC	Excipient
Sandoz Inc	cefpodoxime proxetil	0781-5438	CARBOXYMETHYLCELLULOSE CALCIUM
Sandoz Inc	cefpodoxime proxetil	0781-5438	CROSPOVIDONE
Sandoz Inc	cefpodoxime proxetil	0781-5438	FD&C YELLOW NO. 6
Sandoz Inc	cefpodoxime proxetil	0781-5438	HYDROXYPROPYL CELLULOSE
Sandoz Inc	cefpodoxime proxetil	0781-5438	HYPROMELLOSE
Sandoz Inc	cefpodoxime proxetil	0781-5438	LACTOSE MONOHYDRATE
Sandoz Inc	cefpodoxime proxetil	0781-5438	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in CEFPODOXIME PROXETIL?

# Of NDCs	Excipient
3	ANHYDROUS CITRIC ACID
14	CARBOXYMETHYLCELLULOSE CALCIUM
3	CARBOXYMETHYLCELLULOSE SODIUM
3	CELLULOSE, MICROCRYSTALLINE
3	CROSCARMELLOSE SODIUM
14	CROSPOVIDONE
1	FD&C RED NO. 40

Cefpodoxime Proxetil Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: September 29, 2026

Cefpodoxime proxetil is an off-patent oral third-generation cephalosporin prodrug with established tablet and oral-suspension products. The main formulation opportunity is not basic market entry. It is differentiation through improved aqueous dispersion, taste masking, pediatric acceptability, reconstitution stability, low-dose accuracy, and manufacturing robustness. The highest-value excipient work addresses cefpodoxime proxetil's poor aqueous solubility, ester hydrolysis risk, bitter taste, and dose variability in suspensions.

What is the formulation profile of cefpodoxime proxetil?

Cefpodoxime proxetil is the orally administered ester prodrug of cefpodoxime. After absorption, esterases hydrolyze the proxetil group to release active cefpodoxime. The drug is marketed primarily as immediate-release tablets and powder for oral suspension.

Attribute	Formulation relevance
Drug class	Oral third-generation cephalosporin
Active prodrug	Cefpodoxime proxetil
Active moiety	Cefpodoxime
Typical dosage forms	Film-coated tablets and oral suspension
Main physicochemical issue	Low aqueous solubility and incomplete dissolution
Main sensory issue	Bitter taste from the cephalosporin component
Main chemical risk	Hydrolysis of the ester prodrug and degradation under unfavorable moisture, pH, or temperature conditions
Main patient segment	Adults and children requiring oral antibacterial therapy
Regulatory pathway	Abbreviated New Drug Application for generic products
Biosimilar exposure	None; cefpodoxime proxetil is a small-molecule drug

The proxetil ester improves oral delivery compared with cefpodoxime itself but creates formulation constraints. The product must release the prodrug efficiently while limiting premature degradation during manufacture and storage. For suspensions, the formulation must also provide uniform redispersion and dose delivery after repeated handling.

The FDA label identifies cefpodoxime proxetil tablets and oral suspension as immediate-release products. Product-specific excipient composition varies by manufacturer and dosage form.[1,2]

What excipients are used in cefpodoxime proxetil tablets?

Cefpodoxime proxetil tablets commonly use a conventional direct-compression or granulation platform with film coating. Public product labels identify excipients such as lactose, carboxymethylcellulose calcium, hydroxypropyl cellulose, sodium lauryl sulfate, magnesium stearate, hypromellose, titanium dioxide, and plasticizers or coating aids, depending on the manufacturer.[1,3]

Core tablet excipient functions

Excipient category	Typical function	Strategic consideration
Lactose or other diluent	Bulk and compressibility	May create suitability issues for patients with lactose intolerance and can affect moisture behavior
Hydroxypropyl cellulose	Binder and film former	Supports granule strength and tablet integrity
Carboxymethylcellulose calcium	Disintegrant	Helps tablet breakup and drug release
Sodium lauryl sulfate	Wetting agent	Can improve wetting of poorly soluble drug particles
Magnesium stearate	Lubricant	Excess levels can slow dissolution and reduce tablet tensile strength
Hypromellose	Film coating	Provides mechanical protection and swallowability
Titanium dioxide or equivalent pigment	Opacity and appearance	Regulatory acceptability depends on jurisdiction
Plasticizer	Coating flexibility	Controls cracking and adhesion during storage

The commercial target is a formulation that maintains rapid dissolution without relying on high surfactant loading. Excessive sodium lauryl sulfate can affect tablet performance, mouthfeel, and process behavior. Excess magnesium stearate can create hydrophobic surfaces that reduce dissolution.

A development program should control particle-size distribution, specific surface area, blend uniformity, lubricant mixing time, compression force, and coating weight gain. These variables can materially change dissolution even when the qualitative excipient formula remains unchanged.

What excipients are used in cefpodoxime proxetil oral suspension?

Cefpodoxime proxetil oral suspension generally requires a suspending system, wetting aid, sweetener, flavor, preservative, buffer or pH adjuster, and often a viscosity modifier. Public labeling for products such as Vantin and generic equivalents identifies excipient classes including sucrose, xanthan gum, carboxymethylcellulose sodium, sodium benzoate, silicon dioxide, flavoring agents, and other formulation aids.[1,2]

Oral-suspension excipient architecture

Formulation function	Candidate excipient classes	Primary development risk
Suspending agent	Xanthan gum, sodium carboxymethylcellulose, microcrystalline cellulose combinations	Excess viscosity, poor pourability, sedimentation
Wetting agent	Polysorbates, sodium lauryl sulfate, poloxamers	Foaming, taste, degradation, regulatory limits
Sweetener	Sucrose, sucralose, sodium saccharin, acesulfame potassium	Dental, metabolic, or sensory concerns
Flavor	Fruit flavors, masking systems	Stability and interaction with preservatives
Preservative	Sodium benzoate or alternative antimicrobial system	pH dependence, regulatory and pediatric acceptability
Buffer	Citrate, phosphate, or other buffer systems	Potential impact on ester stability and taste
Opacifier or filler	Silicon dioxide and related materials	Sedimentation and redispersion behavior
Vehicle	Purified water after reconstitution	Microbial control and in-use stability

Cefpodoxime proxetil suspension is a high-value area for formulation improvement because patients and caregivers experience the product directly through taste, dosing, shaking, pouring, and storage. A product that forms a hard sediment, foams excessively, or requires prolonged shaking has practical adherence disadvantages.

What are the main excipient formulation challenges?

Poor aqueous solubility

Cefpodoxime proxetil is poorly soluble in water. The drug therefore behaves as a dispersed solid rather than a fully dissolved active in many suspension systems. Wetting and particle deagglomeration are central formulation objectives.

Useful approaches include:

• Particle-size reduction with control of amorphous content.
• Surfactant-assisted wetting.
• Hydrophilic polymer deposition.
• Drug-resin or lipid-based taste-masking systems.
• Spray-dried or fluid-bed granulated particles.
• Controlled agglomeration to improve flow and redispersion.

Particle engineering must avoid excessive surface-area-driven degradation. Milling can improve dissolution while increasing exposure to moisture, oxygen, and heat.

Ester hydrolysis

The proxetil ester can hydrolyze during processing or storage. Water activity, pH, temperature, and excipient impurities can affect degradation. Hygroscopic excipients and high-moisture manufacturing steps should be evaluated against chemical stability data rather than selected only for manufacturability.

The preferred formulation strategy is usually to minimize aqueous exposure before administration. Dry powder for reconstitution can separate manufacturing stability from in-use suspension performance.

Bitter taste

Bitter taste is a major barrier in pediatric delivery. Increasing sweetness alone often produces an unbalanced sensory profile. More effective systems combine physical taste masking with sweetener and flavor optimization.

Potential technologies include:

• Polymer-coated drug particles.
• Ion-exchange resin complexes.
• Lipid or wax matrices.
• Cyclodextrin complexes.
• Multiparticulate granules.
• Coated mini-tablets or sprinkle particles.
• pH-triggered release systems that limit drug exposure in the mouth.

A taste-masking excipient can alter dissolution and bioavailability. Any taste-masking platform requires comparative dissolution, pharmacokinetic, and bioequivalence assessment.

Suspension uniformity

Dose accuracy depends on rapid redispersion and stable particle distribution. A formulation with high viscosity may resist sedimentation but can be difficult for children or caregivers to pour. A low-viscosity suspension may pour well but settle rapidly.

Critical quality attributes include:

• Sedimentation volume.
• Redispersibility after defined storage intervals.
• Particle-size distribution.
• Pourability.
• Delivered dose uniformity.
• Viscosity across shear rates.
• Microbial quality.
• Reconstituted shelf life.
• In-use stability.

What formulations are protected by cefpodoxime proxetil patents?

The original cefpodoxime and cefpodoxime proxetil composition patents are expired in the United States. The early patent estate covered the cephalosporin compounds and related prodrug forms rather than a modern, commercially differentiated excipient platform. Cefpodoxime proxetil products entered the generic market after expiration of the pioneering compound and product protection.

The key legal distinction is between expired compound patents and potentially enforceable later patents covering:

• Specific taste-masked particles.
• Narrow excipient ratios.
• Stabilized suspension systems.
• Controlled-release or multiparticulate dosage forms.
• Manufacturing processes.
• Specific polymorphs or solid-state forms.
• Combination products.
• Pediatric delivery devices.

A new formulation patent must provide a technically credible distinction from routine optimization. Broad claims directed only to using a conventional suspending agent, sweetener, or wetting agent with cefpodoxime proxetil would face substantial obviousness risk.

Patent-strength assessment

Patent subject	Likely strength	Commercial value
Basic cefpodoxime proxetil compound	Expired	No current blocking value
Conventional tablet excipients	Low	Limited exclusionary value
Conventional suspension with sugar and xanthan gum	Low to moderate	Weak unless tied to unexpected performance
Defined taste-masked microparticles	Moderate to strong	Potential pediatric differentiation
Stabilized dry powder with defined water activity	Moderate	Manufacturing and shelf-life value
Novel reconstitution system	Moderate	Device and lifecycle opportunity
New route or delivery technology	Variable	Depends on clinical and bioequivalence evidence
Manufacturing process with improved impurity profile	Moderate	Can create process know-how and possible patent protection

When does cefpodoxime proxetil lose exclusivity?

Cefpodoxime proxetil lost U.S. market exclusivity years ago. The original U.S. patent protection for the cefpodoxime chemical series was associated with patents filed in the 1980s and has expired under the pre-1995 patent term framework. FDA-approved generic cefpodoxime proxetil products demonstrate that the market is open to ANDA competition.[4,5]

The relevant commercial question is no longer loss of basic exclusivity. It is whether a company can establish a defensible product-level advantage in a crowded generic category.

What is the Orange Book status of cefpodoxime proxetil?

Cefpodoxime proxetil has FDA-approved reference products and generic products listed through the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book.[4] The reference product Vantin was marketed by Pharmacia and later associated with Pfizer’s product portfolio. Generic approvals have been granted for tablets and oral suspension.

For an applicant, the practical Orange Book analysis should focus on:

• Whether the reference NDA has active listed patents.
• Whether any listed patents cover the intended dosage form.
• Whether a Paragraph IV certification is required.
• Whether the proposed product uses the same route, dosage form, strength, and conditions of use.
• Whether a 30-month stay could apply to a listed patent challenge.

For an old, genericized small-molecule product, the main filing risk is generally bioequivalence, CMC performance, stability, and product-quality execution rather than an active compound patent barrier.

Which companies are challenging cefpodoxime proxetil exclusivity?

Generic manufacturers have already established market access for cefpodoxime proxetil through FDA-approved ANDAs. Publicly identifiable generic suppliers have included companies such as Lupin, Ranbaxy, Sandoz, and other authorized or approved generic manufacturers, subject to product-specific approval and marketing status.[4,5]

The market does not present a biosimilar challenge because cefpodoxime proxetil is a chemically synthesized small molecule, not a biologic. Applicants use the ANDA pathway rather than the abbreviated biologics license application pathway.

Are there Paragraph IV risks for cefpodoxime proxetil?

Paragraph IV risk is low for the basic tablet and suspension products because the foundational compound protection has expired and the product has long been genericized. A Paragraph IV certification could still arise if a sponsor seeks approval while a later patent is listed for a particular formulation, method of use, or delivery system.

The most credible Paragraph IV scenarios would involve:

1. A newly patented taste-masking platform.
2. A patented pediatric suspension with defined stability characteristics.
3. A protected modified-release product.
4. A device-linked formulation with a listed patent.
5. A newly approved indication supported by a method-of-use patent.

A conventional immediate-release tablet or suspension using standard excipients is unlikely to create a meaningful patent dispute unless a later-listed patent is unusually broad.

What commercial opportunities exist in cefpodoxime proxetil excipients?

Pediatric taste-masked suspension

The strongest opportunity is a pediatric suspension with improved taste, low sedimentation, rapid redispersion, and accurate dosing. A product can compete without changing the active ingredient if it improves caregiver experience and treatment completion.

Potential commercial claims include:

• Reduced bitterness.
• No vigorous shaking requirement.
• Lower viscosity with reliable dose uniformity.
• Longer in-use stability after reconstitution.
• Reduced preservative burden.
• Improved acceptance in pediatric taste panels.

Claims must be supported by validated sensory, pharmaceutical, and clinical data.

High-concentration suspension

A higher-concentration suspension could reduce dosing volume. This is commercially attractive for children who resist large volumes. The main technical constraints are sedimentation, viscosity, taste intensity, dose uniformity, and gastrointestinal tolerability.

The product would need a robust demonstration that the higher concentration does not reduce dissolution or create dose stratification after storage.

Sprinkle formulation

A coated granule or mini-tablet formulation could target children who cannot swallow tablets but can take medicine with soft food. The key requirements are:

• Minimal bitterness during chewing.
• Stability in the selected food vehicle.
• No significant dose loss from residue.
• Rapid release after administration.
• Compatibility with pediatric feeding practices.

Sprinkle products can be differentiated through particle coating and packaging, but they require careful labeling around food mixing and immediate administration.

Lactose-free and simplified-excipient tablets

A lactose-free tablet may address patient preference and excipient avoidance. This opportunity is commercially narrower than pediatric taste masking but may simplify global product positioning. Substitution of lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or other diluents must preserve dissolution and tablet robustness.

Extended shelf-life dry powder

A dry powder with improved moisture control could offer longer labeled shelf life or improved reconstituted stability. The commercial value depends on whether the stability improvement reduces distribution losses or expands markets with less reliable temperature control.

Manufacturing and CDMO services

Cefpodoxime proxetil is suitable for contract development organizations with capabilities in:

• Low-dose blend uniformity.
• Moisture-controlled granulation.
• Film coating.
• Spray drying.
• Taste-masked multiparticulates.
• Dry powder suspension manufacture.
• Pediatric sensory testing.
• In-use suspension stability.

The most defensible service offering is a platform that links particle engineering, excipient screening, dissolution, taste masking, and scale-up.

How does cefpodoxime proxetil compare with competing oral cephalosporins?

Product	Formulation opportunity	Competitive consideration
Cefpodoxime proxetil	Taste masking, suspension stability, lower-volume pediatric dosing	Established generic competition
Cefdinir	Pediatric suspension and color/taste management	Strong generic and pediatric presence
Cefuroxime axetil	Solubility and food-effect management	Distinct pharmacokinetic constraints
Cephalexin	Simple, low-cost oral delivery	High generic price pressure
Cefixime	Pediatric suspension and dosing convenience	Broad generic competition
Cefaclor	Suspension stability and sensory performance	Older product with generic competition

Cefpodoxime proxetil can compete where prescribers value its spectrum, dosing schedule, or clinical familiarity. A new excipient strategy should target a measurable product disadvantage rather than attempt to compete solely on price.

What regulatory pathway applies to a new cefpodoxime proxetil formulation?

A conventional tablet or suspension relying on the same active ingredient, route, dosage form, strength, and conditions of use would generally be developed through the ANDA pathway if therapeutic equivalence can be demonstrated.[6]

A materially different dosage form, delivery system, or release profile may require a different regulatory strategy. Regulatory risk increases when the formulation:

• Changes the release mechanism.
• Uses a novel route of administration.
• Claims a new indication.
• Alters the dosing frequency.
• Introduces a complex drug-device combination.
• Depends on clinical superiority rather than equivalence.

For a standard generic product, development should prioritize comparative dissolution, impurity profiling, stability, content uniformity, microbial control for suspension, and bioequivalence. The FDA’s product-specific guidance, where available, should control study design.[6]

What generic launch scenarios exist?

Low-cost conventional launch

A manufacturer can enter with a conventional tablet or suspension using established excipients. This has the lowest technical risk but also the weakest differentiation and highest price pressure.

Pediatric-premium launch

A sponsor can launch a taste-masked suspension or sprinkle product. The product may support higher pricing if it demonstrates better acceptance, lower dosing burden, or improved handling.

Hospital and institutional launch

A supplier can target hospital formularies, outpatient clinics, and public procurement. The critical factors are supply reliability, packaging, shelf life, and total acquisition cost.

Regional launch

Markets with limited access to pediatric oral cephalosporins may value stable dry powders and simple reconstitution. Geographic strategy must account for local excipient permissions, preservative rules, labeling requirements, and antimicrobial stewardship policies.

What is the revenue exposure and market outlook?

Cefpodoxime proxetil revenue is exposed to generic price erosion, multiple suppliers, tender purchasing, and substitution. The basic molecule is unlikely to support premium pricing without a differentiated delivery system.

Revenue opportunity is concentrated in:

• Pediatric products.
• Branded generics.
• Difficult-to-manufacture suspensions.
• Hospital and government contracts.
• Markets where reliable supply is more important than lowest unit price.
• Licensing of taste-masking or particle-engineering technology.

A sponsor should model revenue by dosage form rather than aggregate molecule sales. Tablets may generate volume but limited margin. Pediatric suspensions and differentiated multiparticulates can generate higher gross margin if protected by formulation know-how, patents, trade secrets, or brand preference.

Key Takeaways

• Cefpodoxime proxetil is an off-patent oral cephalosporin prodrug with established generic competition.
• The main formulation problems are poor aqueous solubility, ester hydrolysis, bitter taste, sedimentation, and dose uniformity.
• Conventional tablet excipients provide limited differentiation and weak patent leverage.
• Pediatric taste-masked suspension, high-concentration suspension, sprinkle granules, and improved dry-powder systems offer the strongest commercial opportunities.
• A new formulation patent must rely on defined technical features and unexpected performance, not routine selection of common excipients.
• Paragraph IV and Orange Book risks are low for conventional products but can arise from later patents covering novel delivery systems or pediatric formulations.
• Biosimilar competition is irrelevant because cefpodoxime proxetil is a small molecule.
• Regulatory success depends on formulation-specific bioequivalence, dissolution, stability, microbial control, and dose-delivery data.
• The best business case combines excipient differentiation with pediatric usability, reliable manufacturing, and a focused geographic or institutional launch strategy.

FAQs

Can cefpodoxime proxetil be formulated as an orally disintegrating tablet?

Yes, but the formulation must address taste masking, drug loading, tablet friability, moisture sensitivity, and rapid release. An orally disintegrating tablet would require strong sensory performance because the drug remains in the mouth longer than a conventional swallowed tablet.

Is a preservative-free cefpodoxime proxetil suspension commercially practical?

It is technically possible, but the product would need a validated antimicrobial-control strategy based on packaging, water activity, reconstitution conditions, and in-use stability. A preservative-free formulation may be more attractive for specific pediatric or institutional segments.

Which excipient is most important for cefpodoxime proxetil suspension stability?

No single excipient determines stability. The combined system of suspending polymer, wetting agent, vehicle pH, preservative, moisture control, particle size, and packaging determines performance.

Can cefpodoxime proxetil be protected by a new formulation patent?

Yes. Protection is more credible for a defined taste-masked particle, stabilized suspension, novel reconstitution system, or manufacturing process with demonstrated technical advantages than for a routine tablet formula.

Is cefpodoxime proxetil suitable for a fixed-dose combination product?

Potentially, but the combination would require compatibility, stability, dose-ratio, bioequivalence, and regulatory justification. The partner active must be selected around compatible pH, moisture, dissolution, and dosing requirements.

References

1. U.S. Food and Drug Administration. (2012). Vantin (cefpodoxime proxetil) tablets and oral suspension prescribing information. FDA-approved labeling.

2. DailyMed. (n.d.). Cefpodoxime proxetil tablet and powder for suspension prescribing information. National Library of Medicine.

3. U.S. National Library of Medicine. (n.d.). Cefpodoxime proxetil: Drug label information and inactive ingredients. DailyMed.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

5. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drug products. FDA.

6. U.S. Food and Drug Administration. (n.d.). ANDA submissions: Content and format. Center for Drug Evaluation and Research.